FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2447 June 14, 2007 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Khuri, F. R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

When erythropoietin won market approval in 1988, it was hailed as a wonder drug because of the selectivity of its action and its resulting relative freedom from untoward effects. This selective action was due largely to the restricted expression of its receptor on erythroid progenitors. As is common with "wonder" drugs, however, things turned out not to be quite so simple. Over the ensuing years, functional erythropoietin receptors have been shown to be present on other types of cells, but these findings have had little effect on the therapeutic uses of erythropoietin — although some of them could be advantageous . . . [Full Text of this Article]

Source Information

Dr. Longmore is an associate professor of medicine and cell biology at Washington University, St. Louis.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.